Abstract
Based on atypical cultivable non-pathogenic mycobacteria, a vaccine with immunoprophylactic cum immuno-therapeutic properties against leprosy was developed by us many years back. The gene sequence of Mw (code word) is now known and it has been named as Mycobacterium indicus pranii (MIP). Besides Leprosy, MIP has also remarkable capabilities for treatment of tuberculosis including category II, “Difficult to treat” tuberculosis. What is further impressive is its ability to cure ugly ano-genital warts. It has therapeutic action against Myelomas. MIP activated T cells and cytokines, particularly ƴ-interferon play a major role in action of MIP against cancer cells. Combination of MIP with cyclophosphamide improves anti-tumour activity.
MIP is a potent invigorator of immune responses and is being employed as an adjuvant in a potential Birth Control Vaccine against hCG, currently under development. MIP is approved by the Drugs Controller General of India & US FDA. It is licensed to a company for availability to public in India and elsewhere in the world. Very recently, a trial has been launched by CSIR, Ministry of Science and Technology on the utility of Mw (MIP) to cure those individuals who are infected with Corona and protect family members if possible by immuno-prophylaxis.
Publisher
Uniscience Publishers LLC
Reference30 articles.
1. Talwar GP (1999) “An immunotherapeutic vaccine for multibacillary leprosy”. Int Rev Immunol 18(3): 229-249.
2. Talwar GP, Krishnan AD, Jha P, Mehra V (1974) “Intracellular Growth of an obligatory parasite Mycobacterium leprae. Host Bacterial Interactions”. Biochimie 56: 231-237.
3. Chaudhuri S, Fotedar A, Talwar GP (1983) “Lepromin conversion in repeatedly lepromin negative BL/LL patients after immunization with autoclaved Mycobacterium W”. Int J Lepr & Other Mycobact Dis 51(2):159-68.
4. Talwar GP, Gupta JC, Mustafa AS, Kar HK, Katoch K, Parida SK, Reddi PP, Ahmed N, Saini V, Gupta S (2017) “Development of a potent invigorator of immune responses endowed with both preventive and therapeutic properties”. Biologics: Targets & Therapy 11:55-63.
5. Zaheer S. A, Mukherjee A, Ramesh V et al (1995) “Immunotherapy benefits multibacillary patients with persistently high bacteriological index despite long term multidrug therapy”. Immunol Infect Dis 5:115-122.